My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 88

    1.

    Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes.

    List JF, Woo V, Morales E, Tang W, Fiedorek FT.

    Diabetes Care. 2009 Apr;32(4):650-7. Epub 2008 Dec 29.PMID: 19114612 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment.

    Wilding JP, Norwood P, T'joen C, Bastien A, List JF, Fiedorek FT.

    Diabetes Care. 2009 Sep;32(9):1656-62. Epub 2009 Jun 15.PMID: 19528367 [PubMed - indexed for MEDLINE]Related articles

    3.

    Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus.

    Komoroski B, Vachharajani N, Feng Y, Li L, Kornhauser D, Pfister M.

    Clin Pharmacol Ther. 2009 May;85(5):513-9. Epub 2009 Jan 7. Erratum in: Clin Pharmacol Ther. 2009 May;85(5):558. PMID: 19129749 [PubMed - indexed for MEDLINE]Related articles

    4.

    Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.

    Charbonnel B, Karasik A, Liu J, Wu M, Meininger G; Sitagliptin Study 020 Group.

    Diabetes Care. 2006 Dec;29(12):2638-43.PMID: 17130197 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats.

    Han S, Hagan DL, Taylor JR, Xin L, Meng W, Biller SA, Wetterau JR, Washburn WN, Whaley JM.

    Diabetes. 2008 Jun;57(6):1723-9. Epub 2008 Mar 20.PMID: 18356408 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial.

    Zinman B, Hoogwerf BJ, Durán García S, Milton DR, Giaconia JM, Kim DD, Trautmann ME, Brodows RG.

    Ann Intern Med. 2007 Apr 3;146(7):477-85. Erratum in: Ann Intern Med. 2007 Jun 19;146(12):896. PMID: 17404349 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects.

    Komoroski B, Vachharajani N, Boulton D, Kornhauser D, Geraldes M, Li L, Pfister M.

    Clin Pharmacol Ther. 2009 May;85(5):520-6. Epub 2009 Jan 7.PMID: 19129748 [PubMed - indexed for MEDLINE]Related articles

    8.

    Reduction of glycosylated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM. A placebo-controlled dose-comparison study.

    Coniff RF, Shapiro JA, Robbins D, Kleinfield R, Seaton TB, Beisswenger P, McGill JB.

    Diabetes Care. 1995 Jun;18(6):817-24.PMID: 7555508 [PubMed - indexed for MEDLINE]Related articles

    9.

    The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control.

    Robinson AC, Burke J, Robinson S, Johnston DG, Elkeles RS.

    Diabetes Care. 1998 May;21(5):701-5.PMID: 9589227 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study.

    Moretto TJ, Milton DR, Ridge TD, Macconell LA, Okerson T, Wolka AM, Brodows RG.

    Clin Ther. 2008 Aug;30(8):1448-60. Erratum in: Clin Ther. 2008 Oct;30(10):1937. PMID: 18803987 [PubMed - indexed for MEDLINE]Related articles

    11.

    Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM. Results of two multicenter, randomized, placebo-controlled clinical trials. The Glipizide Gastrointestinal Therapeutic System Study Group.

    Simonson DC, Kourides IA, Feinglos M, Shamoon H, Fischette CT.

    Diabetes Care. 1997 Apr;20(4):597-606.PMID: 9096986 [PubMed - indexed for MEDLINE]Related articles

    12.

    Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes.

    Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE; Sitagliptin 036 Study Group.

    Diabetes Care. 2007 Aug;30(8):1979-87. Epub 2007 May 7. Erratum in: Diabetes Care. 2008 Aug;31(8):1713. PMID: 17485570 [PubMed - indexed for MEDLINE]Related articlesFree article

    13.

    Comparison of extended-release metformin in combination with a sulfonylurea (glyburide) to sulfonylurea monotherapy in adult patients with type 2 diabetes: a multicenter, double-blind, randomized, controlled, phase III study.

    Lewin A, Lipetz R, Wu J, Schwartz S.

    Clin Ther. 2007 May;29(5):844-55.PMID: 17697903 [PubMed - indexed for MEDLINE]Related articles

    14.

    Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study.

    Roberts VL, Stewart J, Issa M, Lake B, Melis R.

    Clin Ther. 2005 Oct;27(10):1535-47.PMID: 16330290 [PubMed - indexed for MEDLINE]Related articles

    15.

    Results of the glucose-lowering effect of WelChol study (GLOWS): a randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes.

    Zieve FJ, Kalin MF, Schwartz SL, Jones MR, Bailey WL.

    Clin Ther. 2007 Jan;29(1):74-83.PMID: 17379048 [PubMed - indexed for MEDLINE]Related articles

    16.

    Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial.

    Madsbad S, Schmitz O, Ranstam J, Jakobsen G, Matthews DR; NN2211-1310 International Study Group.

    Diabetes Care. 2004 Jun;27(6):1335-42.PMID: 15161785 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial.

    Fonseca V, Rosenstock J, Patwardhan R, Salzman A.

    JAMA. 2000 Apr 5;283(13):1695-702. Erratum in: JAMA 2000 Sep 20;284(11):1384. PMID: 10755495 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    A double-masked placebo-controlled trial assessing effects of various doses of BTS 67,582, a novel insulinotropic agent, on fasting hyperglycemia in NIDDM patients.

    Skillman CA, Raskin P.

    Diabetes Care. 1997 Apr;20(4):591-6.PMID: 9096985 [PubMed - indexed for MEDLINE]Related articles

    19.

    Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes.

    Covington P, Christopher R, Davenport M, Fleck P, Mekki QA, Wann ER, Karim A.

    Clin Ther. 2008 Mar;30(3):499-512.PMID: 18405788 [PubMed - indexed for MEDLINE]Related articles

    20.

    Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes.

    Horton ES, Clinkingbeard C, Gatlin M, Foley J, Mallows S, Shen S.

    Diabetes Care. 2000 Nov;23(11):1660-5.PMID: 11092289 [PubMed - indexed for MEDLINE]Related articlesFree article

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity